Endocannabinoid enhancer

{{Short description|Type of cannabinoidergic drug}}

An endocannabinoid enhancer (eCBE) is a type of cannabinoidergic{{cite book|author1=George I. Papakostas|author2=Maurizio Fava|title=Pharmacotherapy for Depression and Treatment-resistant Depression|url=https://books.google.com/books?id=zigp-66vq0MC&pg=PA323|year=2010|publisher=World Scientific|isbn=978-981-4287-59-3|pages=323–}} drug that enhances the activity of the endocannabinoid system by increasing extracellular concentrations of endocannabinoids.{{cite journal|last1=Bambico|first1=Francis Rodriguez|last2=Gobbi|author2-link=Gabriella Gobbi|first2=Gabriella|title=The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets|journal=Expert Opinion on Therapeutic Targets|volume=12|issue=11|year=2008|pages=1347–1366|issn=1472-8222|doi=10.1517/14728222.12.11.1347|pmid=18851692|s2cid=86111417}}{{cite journal|last1=Di Marzo|first1=Vincenzo|title=Targeting the endocannabinoid system: to enhance or reduce?|journal=Nature Reviews Drug Discovery|volume=7|issue=5|year=2008|pages=438–455|issn=1474-1776|doi=10.1038/nrd2553|pmid=18446159|s2cid=21081378}}{{cite journal|last1=Saito|first1=Viviane M.|last2=Wotjak|first2=Carsten T.|last3=Moreira|first3=Fabrício A.|title=Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders?|journal=Rev Bras Psiquiatr|volume=32|issue=1|year=2010|pages=57–514|pmid=20512266|issn=1516-4446|doi=10.1590/S1516-44462010000500004|doi-access=free}}{{cite journal|last1=Micale|first1=Vincenzo|last2=Di Marzo|first2=Vincenzo|last3=Sulcova|first3=Alexandra|last4=Wotjak|first4=Carsten T.|last5=Drago|first5=Filippo|title=Endocannabinoid system and mood disorders: Priming a target for new therapies|journal=Pharmacology & Therapeutics|volume=138|issue=1|year=2013|pages=18–37|issn=0163-7258|doi=10.1016/j.pharmthera.2012.12.002|pmid=23261685}} Examples of different types of eCBEs include fatty acid amide hydrolase (FAAH) inhibitors, monoacylglycerol lipase (MAGL) inhibitors, and endocannabinoid transporter (eCBT) inhibitors (or "endocannabinoid reuptake inhibitors" ("eCBRIs")). An example of an actual eCBE is AM404, the active metabolite of the analgesic paracetamol (acetaminophen; Tylenol) and a dual FAAH inhibitor and eCBRI.{{cite journal | vauthors = Giuffrida A, Beltramo M, Piomelli D | title = Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology | journal = J. Pharmacol. Exp. Ther. | volume = 298 | issue = 1 | pages = 7–14 | year = 2001 | doi = 10.1016/S0022-3565(24)29345-9 | pmid = 11408519 | url = https://www.escholarship.org/uc/item/0n88f85c }}{{cite journal | vauthors = Anderson BJ | title = Paracetamol (Acetaminophen): mechanisms of action | journal = Paediatr Anaesth | volume = 18 | issue = 10 | pages = 915–21 | year = 2008 | pmid = 18811827 | doi = 10.1111/j.1460-9592.2008.02764.x | s2cid = 17115356 | doi-access = free }}{{cite journal | vauthors = Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S | title = Paracetamol: new vistas of an old drug | journal = CNS Drug Rev | volume = 12 | issue = 3–4 | pages = 250–75 | year = 2006 | pmid = 17227290 | doi = 10.1111/j.1527-3458.2006.00250.x | pmc = 6506194 }}